InveniAI Announces Launch of AlphaMeld Corporation and Major Milestone Updates to Reflect Cutting-Edge Innovation in AI-Driven Drug Discovery GUILFORD, Conn., Jan. 13, 2025 (GLOBE NEWSWIRE) -- InveniAI LLC, a global leader in the application of artificial intelligence (AI), machine learning (ML), and generative AI tools to revolutionize...

InveniAI Announces Collaboration with Ono Pharmaceutical for Target Discovery Teams will work together by leveraging InveniAI's technology platform to identify, evaluate, and optimize novel targets across Ono’s diseases of interestOno will access InveniAI’s AI platform...

InveniAI's AlphaMeld Platform Debuts the Addition of ChatAlphaMeld™, A Powerful Tool Designed to Scale Target and Drug Discovery and Development Powered by GPT-4, ChatAlphaMeld enables user interaction across functional stakeholders to automate hypothesis generation and prioritization Integrated into the AlphaMeld workflow, ChatAlphaMeld is...

InveniAI and Kyowa Kirin Expand AI-Driven Partnership to a Multi-Year Strategic Collaboration for the Discovery of Novel Targets and Treatments Across Therapeutic Areas Collaboration enables Kyowa Kirin's R&D team to access InveniAI's data-driven discovery platform in expanded therapeutic areasInveniAI's AlphaMeld® platform to provide unique Translational Edge...